Correction of ischemic optic neuropathy in rats by carbamylated darbepoetin

The protective effects of carbamylated darbepoetin on the model of ischemic optic neuropathy in rats were revealed. To increase the effectiveness of pharmacological correction of experimental ischemic optic neuropathy in an experiment by using carbamylated darbepoetin. Measuring the microcirculation level in the retina of rats was carried out using laser Doppler flowmetry (LDF

A comparative evaluation of the efficacy of dimethylaminoethanol derivative 7-16, C7070 and picamilon in correction of experimental hypertensive neuroretinopathy

The efficacy of dimethylaminoethanol (DMAE) derivative 7-16, substance C7070 in comparison with picamylon in hypertensive neuroretinopathy model in white laboratory rats was evaluate

Correction of retinal angiopathy of hypertensive type by dimethylaminoethanol derivative 19-16 in experiment

To increase the effectiveness of pharmacological correction of retinal angiopathy of hypertensive type using a new dimethylaminoethanol (DMAE) derivative 19-1

Correction of retinal angiopathy of hypertensive type by minoxidil, sildenafil in experiment

For the study of retinoprotective properties of pharmacological agents a model of retinal angiopathy of hypertensive type was created against the background of N-nitro-L-arginine methyl ester (L-NAME) administration in a dose 12.5 mg/kg rat body weight for 28 days. Detection of preconditioning properties of pharmacological agents may be a new approach in the correction and prevention of retinal angiopathy, which is the initial part of hypertensive retinopath

Correction of Experimental Retinal Ischemia by L-Isomer of Ethylmethylhydroxypyridine Malate

An important task of pharmacology and ophtalmology is to find specific and highly effective agents for correcting retinal ischemia. The objective of this study is to increase the effectiveness of pharmacological correction of retinal ischemia by using new 3-hydroxypyridine derivative-L-isomer of ethylmethylhydroxypyridine malat

The development of hypertensive neuroretinopathy model on wistar rats

A model of hypertensive neuroretinopathy was developed on Wistar line rats with administration of non-selective NO-synthase blocker N-nitro-L-arginine methyl ester (L-NAME) in a dose 12.5 mg/kg within 28 days on the background of single increased intraocular pressure (IOP) to 110 mmHg. As a result of the interim evaluation of pathology simulation mode the most optimal was a model of hypertensive neuroretinopathy with 5-minute increased IOP at day 26 of the experiment on the background of L-NAME for further study of neuroretinoprotective properties of pharmacological agent

Correction of retinal ischemia/reperfusion by 3-(1H-benzimidazol-2-il)-1,2,2-trimethyl cyclopentancarbonic acid in experiment

Results of ocular fundus studies revealed the most pronounced protective effects of 3-(1Hbenzimidazol-2-il)-1,2,2-trimethyl cyclopentancarbonic acid in a dose 50 mg/kg on the model of retinal ischemiareperfusion in Wistar rats, which is reflected in the restoration of the optic disc. Correction of retinal ischemiareperfusion by 3-(1H-benzimidazol-2-il)-1,2,2-trimethyl cyclopentancarbonic acid in a dose 50 mg/kg leads to higher values of the coefficient b/a of electroretinography after 72 hours of reperfusion compared to the group with pathology correction by the same drug in a dose 10 mg/kg, which indicates the restoration of the electrophysiological state of the retin

Pharmacological preconditioning by recombinant erythropoietin as the possibility of increasing the stability of tissue of the retina to reperfusion ischemia in experiment

Ischemic injury was formed in laboratory rats by applying mechanical pressure (110 mm Hg) to the anterior eye chamber for 30 minutes. The experiment revealed that the recombinant erythropoietin (50 IU/kg) prevents the development of degenerative changes in retinal layers caused by ischemic injur

Pharmacological correction of retinal ischemia/reperfusion by minoxidil

The objective of this paper was to increase the effectiveness of pharmacological correction of retinal ischemia-reperfusion by using minoxidil. Minoxidil at a dose of 0.5 mg/kg of rat mass protects the retina from ischemic-reperfusion injury. Protective effects of minoxidil are carried out by a preconditioning action, as evidenced by the lack of positive effects with the administration of glibenclamid

Study to Investigate the anti-inflammatory effect of Codelac® Broncho with Thymus Serpyllum (elixir) in comparison with reference drug Fenspiride (syrup) using accute carrageenan-induced paw inflammation model

Evaluation of anti-inflammatory action of Codelac® Broncho with Thymus Serpyllum (elixir) in comparison with Fenspiride was carried out on the model of acute carrageenan inflammation of the paws in rats. As a result of the study, it turned out that obtained data indicate a more pronounced anti-inflammatory activity of Codelac® Broncho with Thymus Serpyllum in comparison with Fenspiride, on the model of acute carrageenan inflammation of the paw in rat